Design of human granzyme B variants resistant to serpin B9.
Human granzyme B (hGB) is a serine protease involved in immune-mediated apoptosis. Its cytotoxicity makes it potentially applicable in cancer therapy. However, the effectiveness of hGB can be hampered by the cytosolic expression of a natural protein inhibitor, human Serpin B9 (hSB9). Here, we used computational approaches to identify hGB mutations that can affect its binding to hSB9 without significantly decreasing its catalytic efficiency. Alanine-scanning calculations allowed us to identify residues of hGB important for the interaction with hSB9. Some variants were selected, and molecular dynamic simulations on the mutated hGB in complex with hSB9 in aqueous solution were carried out to investigate the effect of these variants on the stability of the complex. The R28K, R201A, and R201K mutants significantly destabilized the interaction of the protein with hSB9. Consistently, all of these variants also retained their activity in the presence of the Serpin B9 inhibitor in subsequent in vitro assays of wild-type and mutated hGB. In particular, the activity of R201K hGB with and without Serpin B9 is very similar to that of the wild-type protein. Hence, R201K hGB emerges as a promising species for antitumoral therapy applications.
Computational Biophysics, German Research School for Simulation Sciences, Jülich D-52425, Germany.
Valeria
V
Losasso
Sonja
S
Schiffer
Stefan
S
Barth
Paolo
P
Carloni
D000595:Amino Acid Sequence; D000818:Animals; D053804:Granzymes / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics; D011485:Protein Binding; D015202:Protein Engineering; D051381:Rats; D016415:Sequence Alignment; D015843:Serpins / Q000737:chemistry / Q000378:metabolism*
C102316:SERPINB9 protein, human; D015843:Serpins; D053804:Granzymes